ABVX.PA Stock - Abivax S.A.
Unlock GoAI Insights for ABVX.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.79M | $4.62M | $4.58M | $37,000 | $14,000 |
| Gross Profit | $10.79M | $4.49M | $4.51M | $-119,000 | $-52,000 |
| Gross Margin | 100.0% | 97.2% | 98.5% | -321.6% | -371.4% |
| Operating Income | $-185,432,000 | $-127,376,000 | $-64,836,000 | $-52,187,000 | $-39,595,000 |
| Net Income | $-176,242,000 | $-147,740,000 | $-60,740,000 | $-42,452,000 | $-37,551,000 |
| Net Margin | -1633.1% | -3197.1% | -1325.3% | -114735.1% | -268221.4% |
| EPS | $-2.80 | $-3.43 | $-3.18 | $-2.75 | $-2.62 |
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
Visit WebsiteEarnings History & Surprises
ABVX.PAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 23, 2026 | — | — | — | — |
Q4 2025 | Dec 15, 2025 | $-0.68 | $-2.10 | -209.1% | ✗ MISS |
Q2 2025 | Jun 2, 2025 | $-0.70 | $-1.50 | -114.0% | ✗ MISS |
Q4 2024 | Nov 15, 2024 | $-1.37 | $-1.30 | +5.5% | ✓ BEAT |
Q2 2024 | Apr 2, 2024 | $-0.85 | $-1.91 | -124.4% | ✗ MISS |
Q3 2023 | Sep 21, 2023 | — | $-1.45 | — | — |
Q1 2023 | Mar 16, 2023 | $-1.76 | $-1.81 | -2.7% | ✗ MISS |
Q2 2022 | Jun 30, 2022 | — | $-1.76 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-1.48 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-1.13 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-1.55 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-1.26 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-1.35 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-1.38 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.82 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.73 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.56 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.57 | — | — |
Q1 2017 | Mar 15, 2017 | — | $-0.61 | — | — |
Q3 2016 | Sep 21, 2016 | — | $-0.86 | — | — |
Latest News
Frequently Asked Questions about ABVX.PA
What is ABVX.PA's current stock price?
What is the analyst price target for ABVX.PA?
What sector is Abivax S.A. in?
What is ABVX.PA's market cap?
Does ABVX.PA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ABVX.PA for comparison